Inhibitory effects and mechanism of SAHA combined with Erlotinib on EGFR-TKI resistant lung cancer cell line H1975 cells

VernacularTitle:SAHA联合厄洛替尼对EGFR-TKI耐药肺癌细胞株H1975的生长抑制作用及机制
Author: Lihao CHEN ¹ ; Jiqing HAO
Author Information

1. 安徽医科大学第一附属医院肿瘤内科
Keywords: lung cancer; SAHA; Erlotinib; combination
From: Acta Universitatis Medicinalis Anhui 2018;53(6):851-855
CountryChina
Language:Chinese
Abstract: Objective To investigate the inhibition and possible mechanism of SAHA alone and combined with Er-lotinib on EGFR-TKI resistant lung cancer cell line H1975 cells. Methods The inhibitory effects of SAHA, Erlo-tinib and combined effect on cells were evaluated by CCK-8, colony formation assay and Transwell invasion assay. Western blot analysis was used to analyze the expression of PI3K, AKT, p-AKT, mTOR and p-mTOR protein in cells. Results SAHA and Erlotinib showed growth inhibition effects on H1975 cells with a dose-dependent man-nerand displayed synergistic inhibition effect. The combination of the drugs was significantly stronger than the single drug in the formation and invasion inhibition of tumor cells. The combined group had a strong inhibitory effect on the PI3K/AKT/mTOR signaling pathway. Conclusion SAHA combined with Erlotinib has synergistic inhibitory effects on the growth, cloning and invasion of EGFR-TKI lung cancer cell line H1975, which may be associated with inhibitory effects on the PI3K/AKT/mTOR signaling pathway.